Baudax Bio Announces Orphan Drug Designation Granted by U.S.

Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors

Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors

tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States , Mike Moyer , Gerri Henwood , Baudax Bio , Baudax Bio Inc , Office Of Orphan Products Development , Company Or Baudax Bio , Drug Administration , Bio Announces Orphan Drug Designation Granted , Neuromuscular Blocking Agents , Chief Executive Officer , Investigational New Drug , Clinical Trial , Orphan Products Development , Orphan Drug Designation , Umbilical Cord Blood , Private Securities Litigation Reform Act , Annual Report , Relations Contact ,